Clincosm LogoSign in Get a demo

stage 0is bladder cancer ajcc v8

Showing 1 - 6 of 6
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8

Not yet recruiting
  • High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • PD-L1/IDO Peptide Vaccine
  • Pembrolizumab
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Apr 24, 2023

Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8 Trial in Buffalo (Behavioral

Recruiting
  • Stage 0a Bladder Cancer AJCC v8
  • +2 more
  • Behavioral Dietary Intervention
  • +2 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Sep 26, 2022

Bladder Urothelial Carcinoma In Situ, Infiltrating Bladder Mixed Carcinoma, Stage 0a Bladder Cancer AJCC v8 Trial in Guam,

Recruiting
  • Bladder Urothelial Carcinoma In Situ
  • +4 more
  • Gemcitabine Hydrochloride
  • Pembrolizumab
  • Birmingham, Alabama
  • +379 more
Aug 23, 2022

Remote Telemonitoring of Patient-Generated Physiologic Health

Recruiting
  • Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8
  • +171 more
  • Patient Monitoring
  • Questionnaire Administration
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8 Trial in Seattle

Recruiting
  • Bladder Urothelial Carcinoma In Situ
  • +5 more
  • Acupuncture Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 27, 2022

Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma Trial

Completed
Has Results
  • Recurrent Bladder Urothelial Carcinoma
  • +19 more
  • Erlotinib Hydrochloride
  • Houston, Texas
    M D Anderson Cancer Center
Aug 21, 2020